For expectant mothers, this blood test is used to detect Down syndrome and two other chromosomal abnormalities (Edwards syndrome and Patau syndrome) during pregnancy, without risk to the fetus or mother. The test is non-invasive, i.e., it does not involve any intervention (consisting of maternal blood sampling), and so does not endanger the pregnancy, nor increase the risk of miscarriage or other maternal or fetal complications.
PRENATEST, NIFTY TEST
This test is based on the fact that the presence of an extra chromosome in the genetic make-up of the fetus slightly increases the amount of fetal DNA in the mother's blood. This increase is the first thing the test detects.
The test can be performed after a consultation between 9 and 20 weeks of pregnancy, and can also be used in the case of twin pregnancies.
Its effectiveness has been established in international clinical trials on a large patient population. These studies have shown that the test can detect fetal trisomies and abnormalities in the mother's blood with an accuracy of over 99%. In addition, the sex of the fetus can also be clearly determined.